Back to top
more

Chemours (CC)

(Delayed Data from NYSE)

$12.21 USD

12.21
6,647,088

+0.71 (6.17%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $12.22 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 5% (233 out of 246)

Industry: Chemical - Diversified

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Chemours (CC) Announces Development of New Specialty Fluid

by Zacks Equity Research

Chemours' (CC) introduction of Opteon 2P50 is a critical step in positioning the company to meet a growing challenge brought on by a new era of data transmission.

Zacks Equity Research

Cabot (CBT) Joins US Energy Department's Better Plants Program

by Zacks Equity Research

Cabot (CBT) believes that this engagement with the DOE will help the company boost its energy efficiency performance.

Zacks Equity Research

Chemours (CC) Q2 Earnings Beat, Titanium Technologies Hurt Sales

by Zacks Equity Research

Chemours' (CC) Titanium Technologies sales were hurt by lower volumes due to weaker demand in all regions in Q2.

Zacks Equity Research

Methanex (MEOH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Methanex (MEOH) delivered earnings and revenue surprises of 9.09% and 4.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Huntsman (HUN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Huntsman (HUN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Titanium Technologies Unit Hurt Chemours (CC) Q2 Earnings?

by Zacks Equity Research

Slow demand recovery in the Titanium Technologies segment is expected to have weighed on Chemours' (CC) performance in the second quarter.

Zacks Equity Research

Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline

by Zacks Equity Research

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Chemours (CC) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Chemours (CC) benefits from strong Opteon demand, effective execution, and its cost-reduction and pricing actions.

Zacks Equity Research

Chemours (CC) Stock Up 16% in 3 Months: What's Driving It?

by Zacks Equity Research

Chemours (CC) gains on healthy Opteon demand, strong execution and its cost-reduction and pricing actions.

Zacks Equity Research

Chemours (CC) Gains on Opteon Adoption Amid Demand Woes

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from demand softness in certain areas, it gains on continued Opteon adoption, strong execution and its cost-reduction and pricing actions.

Zacks Equity Research

Chemours (CC) to Divest Glycolic Acid Business to PureTech

by Zacks Equity Research

Chemours (CC) believes that its Glycolic Acid portfolio complements PureTech's growth strategy.

Zacks Equity Research

Strength Seen in Chemours (CC): Can Its 24.1% Jump Turn into More Strength?

by Zacks Equity Research

Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Here's Why You Should Hold Onto Chemours (CC) Stock for Now

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from demand weakness in certain businesses, it gains on healthy Opteon adoption and its pricing actions.

Zacks Equity Research

Chemours (CC) Extends Capacity to Meet Customers' Needs

by Zacks Equity Research

Chemours (CC) offers a portfolio of HFO-1336mzzZ-based products that are more environmentally friendly than non-HFO alternatives.

Zacks Equity Research

Chemours' (CC) Q1 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Lower volumes and currency headwinds on a year-over-year basis, partly offset by higher pricing, impact Chemours' (CC) results in the first quarter.

Zacks Equity Research

Are Investors Undervaluing Chemours (CC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Chemours (CC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Chemours (CC) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Chemours (CC) delivered earnings and revenue surprises of 58.06% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Methanex (MEOH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Methanex (MEOH) delivered earnings and revenue surprises of 20.65% and 6.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Northern Technologies (NTIC) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Northern Technologies (NTIC) delivered earnings and revenue surprises of -44.44% and 10.44%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold Onto Chemours (CC) Stock for Now

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from higher raw material costs, it gains on healthy Opteon demand and its pricing actions.

Zacks Equity Research

Chemours (CC) Posts Break-Even Q4 Earnings, Sales Miss

by Zacks Equity Research

Chemours (CC) gains from increased prices across its segments amid headwinds from higher input cost inflation, adverse currency movements and soft demand in Europe & Asia in Q4.

Zacks Equity Research

Chemours (CC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Chemours (CC) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Chemours (CC) delivered earnings and revenue surprises of -100% and 5.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

FMC (FMC) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

FMC (FMC) delivered earnings and revenue surprises of 2.16% and 7.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?